Icon

Byetta - (250MCG/ML; Injectable, Subcutaneous)

EXENATIDE SYNTHETIC Astrazeneca
250MCG/ML; Injectable, Subcutaneous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
Less Than 5
None
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Yes
**** ** *** *** *** ******* ******* ’*** (*** *, ****), ’*** (*** **, ****), ’*** (*** *, ****), ’***, ’*** (*** **, ****), ’***(*** **, ****), ’*** (*** *, ****) *** *** *********. ***** ****** ***** **** ** **** ******* *** ******* **** ******** ** *** **, **** - ** ******* *** *** *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** **** ********* ** *** ***** ** ***** **** *** ****** *** ******* ** *** **, ****, ******* **** *** *** ******** *** ******* *** ******** ***** ** *** **********. ******* *** ********** ** ******* **** ****** ** **** ***** ** ****** **** ****** *** **** ****** ******* **** ********. ***** *** *** ********* *** **** ***** *** *** ******** ****** *** *** ** **** ** *** ****** ** ****. *** ** *** *** ***** **** *** ** *** **** ****** *** ***** ** *** *********. **** ******* ** ***** ** ** * *** *********** ******* **** ***** *** ****** ****** ***** ** *** ******* *** *** ******* ***********.
Byetta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
**** ******* ******* ******* ******* *******
****** ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ** **** **, **** ******* **** ****** **** ********
****** ** \ ** **** *, **** ******* ******** *** ****** *******
  1. *** **, **** : **** ******** *********** ***** *** **** ** *** ****** * ********* *** ***/*.* ** *** *** ***/*.* ** (*** ***/**) **** ******* ’*** (*** *, ****), ’*** (*** **, ****), ’*** (*** *, ****), ’***, ’*** (*** **, ****), ’***(*** **, ****), ’*** (*** *, ****).
  2. *** **, **** : *********** ***** * **** ******* **** ** ******** ***** ** ********.
  3. *** *, **** : *********** **** ****** *** ****** **** ** ** ******* *** ******* **** ******** ** *** **, **** - ** *******.
  4. *** **, **** : ********** *** ******* **** **** ********* ** *** ***** ** ***** **** *** ****** *** ******* ** *** **, ****.
  5. *** **, **** : ********** ******* **** ******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.